Observational Study for Left Main Disease Treatment（NCT01341327）
贊助者：Seung-Jung Park｜階段：未列階段｜狀態：RECRUITING｜更新日：2026-10-15
適應症：Coronary Artery Disease
台灣相關臨床試驗最新動態
近 30 天本帳本收錄 100 項在台灣有試驗據點的臨床試驗更新。最新：Seung-Jung Park「Observational Study for Left Main Disease Treatment」（未列階段，RECRUITING），2026-10-15更新。
每次查詢最新更新的100項，再依實際台灣據點欄位核對；數量為帳本收錄，非全站完整統計。
Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC（NCT03732677）
贊助者：AstraZeneca｜階段：PHASE3｜狀態：ACTIVE_NOT_RECRUITING｜更新日：2026-10-15
適應症：Muscle Invasive Bladder Cancer
Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)（NCT04701983）
贊助者：Sanofi｜階段：PHASE3｜狀態：COMPLETED｜更新日：2026-10-15
適應症：Chronic Obstructive Pulmonary Disease
A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)（NCT04961996）
贊助者：Hoffmann-La Roche｜階段：PHASE3｜狀態：ACTIVE_NOT_RECRUITING｜更新日：2026-10-15
適應症：Early Breast Cancer
A Study to Evaluate the Safety and Tolerability of Dapirolizumab Pegol in Study Participants With Systemic Lupus Erythematosus（NCT04976322）
贊助者：UCB Biopharma SRL｜階段：PHASE3｜狀態：ENROLLING_BY_INVITATION｜更新日：2026-10-15
適應症：Systemic Lupus Erythematosus
Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis（NCT05126277）
贊助者：Novartis Pharmaceuticals｜階段：PHASE3｜狀態：ACTIVE_NOT_RECRUITING｜更新日：2026-10-15
適應症：Lupus Nephritis
A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria（NCT05196035）
贊助者：Bayer｜階段：PHASE3｜狀態：ACTIVE_NOT_RECRUITING｜更新日：2026-10-15
適應症：Chronic Kidney Disease、Proteinuria
Multinational Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis（NCT05255991）
贊助者：United Therapeutics｜階段：PHASE3｜狀態：COMPLETED｜更新日：2026-10-15
適應症：Idiopathic Pulmonary Fibrosis、Interstitial Lung Disease
Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC)（NCT05263206）
贊助者：Sanofi｜階段：PHASE3｜狀態：RECRUITING｜更新日：2026-10-15
適應症：Pruritus
The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE (WILLOW LTE)（NCT05540327）
贊助者：Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany｜階段：PHASE2｜狀態：ACTIVE_NOT_RECRUITING｜更新日：2026-10-15
適應症：Systemic Lupus Erythematosus
A Study to Evaluate MORF-057 in Adults With Moderately to Severely Active UC（NCT05611671）
贊助者：Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)｜階段：PHASE2｜狀態：COMPLETED｜更新日：2026-10-15
適應症：Inflammatory Bowel Diseases、Colitis, Ulcerative
International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab（NCT05669989）
贊助者：Sanofi｜階段：PHASE2｜狀態：ENROLLING_BY_INVITATION｜更新日：2026-10-15
適應症：Plasma Cell Myeloma
A Study to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometasone Furoate) Versus Salmeterol Xinafoate/Fluticasone Propionate in Children From 12 Years to Less Than 18 Years of Age With Asthma.（NCT05776927）
贊助者：Novartis Pharmaceuticals｜階段：PHASE3｜狀態：RECRUITING｜更新日：2026-10-15
適應症：Asthma
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).（NCT05947851）
贊助者：Merck Sharp & Dohme LLC｜階段：PHASE3｜狀態：RECRUITING｜更新日：2026-10-15
適應症：Leukemia, Lymphocytic, Chronic, B-Cell、Leukemia, Chronic Lymphocytic、Small-Cell Lymphoma、Lymphoma, Small Lymphocytic、CLL、SLL
A Randomized, Double-blind 2-arm, Followed by an Open-label 1-arm, NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome.（NCT05985915）
贊助者：Novartis Pharmaceuticals｜階段：PHASE3｜狀態：ACTIVE_NOT_RECRUITING｜更新日：2026-10-15
適應症：Sjogrens Syndrome
To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL（NCT06072131）
贊助者：Acrotech Biopharma Inc.｜階段：PHASE3｜狀態：ACTIVE_NOT_RECRUITING｜更新日：2026-10-15
適應症：Peripheral T Cell Lymphoma
Brief Behavioral Therapy for Insomnia (BBTi) in Middle-aged and Older Adults With Chronic Insomnia（NCT06073990）
贊助者：National Cheng-Kung University Hospital｜階段：NA｜狀態：ENROLLING_BY_INVITATION｜更新日：2026-10-15
適應症：Chronic Insomnia、Older Adults、Sleep Hygiene、Sleep Health
ACP-204 in Adults With Alzheimer's Disease Psychosis（NCT06159673）
贊助者：ACADIA Pharmaceuticals Inc.｜階段：PHASE2 / PHASE3｜狀態：RECRUITING｜更新日：2026-10-15
適應症：Alzheimer's Disease Psychosis
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)（NCT06170788）
贊助者：Merck Sharp & Dohme LLC｜階段：PHASE3｜狀態：RECRUITING｜更新日：2026-10-15
適應症：Non-small Cell Lung Cancer (NSCLC)
A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis（NCT06215716）
贊助者：Akero Therapeutics, Inc｜階段：PHASE3｜狀態：RECRUITING｜更新日：2026-10-15
適應症：NASH With Fibrosis、MASH With Fibrosis
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)（NCT06312137）
贊助者：Merck Sharp & Dohme LLC｜階段：PHASE3｜狀態：RECRUITING｜更新日：2026-10-15
適應症：Non Small Cell Lung Cancer
AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2（NCT06346392）
贊助者：AstraZeneca｜階段：PHASE3｜狀態：ACTIVE_NOT_RECRUITING｜更新日：2026-10-15
適應症：Gastric Cancer、Gastroesophageal Junction Cancer
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer（NCT06417814）
贊助者：AstraZeneca｜階段：PHASE3｜狀態：ACTIVE_NOT_RECRUITING｜更新日：2026-10-15
適應症：Metastatic Non-small Cell Lung Cancer
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]（NCT06422143）
贊助者：Merck Sharp & Dohme LLC｜階段：PHASE3｜狀態：RECRUITING｜更新日：2026-10-15
適應症：Non-small Cell Lung Cancer、NSCLC
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)（NCT06452277）
贊助者：Bayer｜階段：PHASE3｜狀態：RECRUITING｜更新日：2026-10-15
適應症：Advanced Non-small Cell Lung Cancer, HER2 Mutation
A Study to Learn About the Study Medicine Aztreonam-Avibactam (ATM-AVI) in Infants and Newborns Admitted in Hospitals With Bacterial Infection (CHERISH)（NCT06462235）
贊助者：Pfizer｜階段：PHASE2｜狀態：RECRUITING｜更新日：2026-10-15
適應症：Gram-negative Bacterial Infection
The Effectiveness of Augmented Reality to Enhance CPAP Therapy in OSA Patients（NCT06520592）
贊助者：National Cheng-Kung University Hospital｜階段：NA｜狀態：ENROLLING_BY_INVITATION｜更新日：2026-10-15
適應症：Aherence、Physical Symptoms、Mental Health、Quality of Life
A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus（NCT06617325）
贊助者：UCB Biopharma SRL｜階段：PHASE3｜狀態：RECRUITING｜更新日：2026-10-15
適應症：Systemic Lupus Erythematosus
STarting incrEmental Prescription of Peritoneal Dialysis（NCT06642597）
贊助者：The University of Queensland｜階段：NA｜狀態：RECRUITING｜更新日：2026-10-15
適應症：Peritoneal Dialysis (PD)、Kidney Failure
A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease（NCT06679140）
贊助者：Pfizer｜階段：PHASE3｜狀態：RECRUITING｜更新日：2026-10-15
適應症：COVID-19 SARS-CoV-2 Infection
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)（NCT06799000）
贊助者：Novartis Pharmaceuticals｜階段：PHASE3｜狀態：ACTIVE_NOT_RECRUITING｜更新日：2026-10-15
適應症：Hidradenitis Suppurativa
A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer（NCT06820463）
贊助者：AbbVie｜階段：PHASE2｜狀態：RECRUITING｜更新日：2026-10-15
適應症：Metastatic Colorectal Cancer
Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC（NCT06855277）
贊助者：Novartis Pharmaceuticals｜階段：PHASE3｜狀態：RECRUITING｜更新日：2026-10-15
適應症：Prostate Cancer
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)（NCT06925737）
贊助者：Merck Sharp & Dohme LLC｜階段：PHASE3｜狀態：RECRUITING｜更新日：2026-10-15
適應症：Prostate Cancer、Prostatic Neoplasms
Efanesoctocog Alfa Prophylaxis in Patients With Hemophilia A With Synovial Hypertrophy（NCT06941870）
贊助者：Sanofi｜階段：PHASE4｜狀態：RECRUITING｜更新日：2026-10-15
適應症：Factor VIII Deficiency
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)（NCT07011732）
贊助者：Bristol-Myers Squibb｜階段：PHASE3｜狀態：RECRUITING｜更新日：2026-10-15
適應症：Alzheimer Disease
A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis（NCT07071519）
贊助者：AbbVie｜階段：PHASE3｜狀態：RECRUITING｜更新日：2026-10-15
適應症：Ulcerative Colitis
A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)（NCT07098338）
贊助者：AstraZeneca｜階段：PHASE2｜狀態：RECRUITING｜更新日：2026-10-15
適應症：Non-Small Cell Lung Cancer
Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia（NCT07109219）
贊助者：AstraZeneca｜階段：PHASE1 / PHASE2｜狀態：RECRUITING｜更新日：2026-10-15
適應症：B-cell Acute Lymphoblastic Leukemia (B-ALL)
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies（NCT07177352）
贊助者：Hoffmann-La Roche｜階段：PHASE3｜狀態：RECRUITING｜更新日：2026-10-15
適應症：Alzheimers Disease
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease（NCT07181109）
贊助者：Alnylam Pharmaceuticals｜階段：PHASE3｜狀態：RECRUITING｜更新日：2026-10-15
適應症：High Risk Cardiovascular Disease、Hypertension、High Cardiovascular Risk
A Study to Learn More About How Well Finerenone Works, How Safe it is, and How it Moves Into, Through, and Out of the Body Compared to Placebo When Taken With Standard Treatment in Children With Heart Failure and Left Ventricular Systolic Dysfunction（NCT07188805）
贊助者：Bayer｜階段：PHASE3｜狀態：RECRUITING｜更新日：2026-10-15
適應症：Left Ventricular Systolic Dysfunction、Heart Failure (Pediatric)
A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Children and Young Adults With Heart Failure and Left Ventricular Systolic Dysfunction（NCT07192952）
贊助者：Bayer｜階段：PHASE3｜狀態：RECRUITING｜更新日：2026-10-15
適應症：Left Ventricular Systolic Dysfunction、Heart Failure (Pediatric)
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations（NCT07195695）
贊助者：Boehringer Ingelheim｜階段：PHASE3｜狀態：RECRUITING｜更新日：2026-10-15
適應症：Non-small Cell Lung Cancer
Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis（NCT07284459）
贊助者：Contineum Therapeutics｜階段：PHASE2｜狀態：RECRUITING｜更新日：2026-10-15
適應症：Idiopathic Pulmonary Fibrosis
LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2（NCT07288398）
贊助者：Tenax Therapeutics, Inc.｜階段：PHASE3｜狀態：ACTIVE_NOT_RECRUITING｜更新日：2026-10-15
適應症：Pulmonary Hypertension Associated With HFpEF
Mobile App-Assisted Home Exercise for Musculoskeletal Disorders（NCT07355595）
贊助者：National Yang Ming Chiao Tung University｜階段：NA｜狀態：COMPLETED｜更新日：2026-10-15
適應症：Musculoskeletal Disorders、Low Back Pain、Neck Pain、Shoulder Pain、Knee Pain
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)（NCT07357727）
贊助者：Novartis Pharmaceuticals｜階段：PHASE3｜狀態：RECRUITING｜更新日：2026-10-15
適應症：Primary Myelofibrosis (PMF)、Post-polycythemia Vera Myelofibrosis (PPV-MF)、Post-essential Thrombocythemia Myelofibrosis (PET-MF)
Eye Movement Parameters and Cognitive Functions in Older Adults（NCT07358598）
贊助者：National Sun Yat-sen University｜階段：未列階段｜狀態：RECRUITING｜更新日：2026-10-15
適應症：Cognitive Dysfunction
Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)（NCT07387926）
贊助者：Novartis Pharmaceuticals｜階段：PHASE1 / PHASE2｜狀態：RECRUITING｜更新日：2026-10-15
適應症：Acute Lymphoblastic Leukemia、Leukemia, Lymphoblastic, Acute, Philadelphia-Positive、Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN（NCT07498335）
贊助者：Novartis Pharmaceuticals｜階段：PHASE3｜狀態：RECRUITING｜更新日：2026-10-15
適應症：Berger Disease、Bergers Disease、IgA Nephropathy、Immunoglobulin A Nephropathy、Primary IgAN、Nephritis IgA Type, Nephropathy IgA Type
Wearable Voice-Guided BBTi for Comorbid Insomnia and Sleep Apnea (COMISA)（NCT07521319）
贊助者：National Sun Yat-sen University｜階段：NA｜狀態：RECRUITING｜更新日：2026-10-15
適應症：Comorbid Insomnia and Sleep Apnea、Insomnia、Obstructive Sleep Apnea
A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer（NCT07525206）
贊助者：AbbVie｜階段：PHASE3｜狀態：RECRUITING｜更新日：2026-10-15
適應症：Colorectal Cancer
A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)（NCT07634471）
贊助者：Merck Sharp & Dohme LLC｜階段：PHASE2 / PHASE3｜狀態：RECRUITING｜更新日：2026-10-15
適應症：Follicular Lymphoma
Sleep, Music, And Research Trial 2.0（NCT07696442）
贊助者：National Taiwan University Hospital｜階段：NA｜狀態：RECRUITING｜更新日：2026-10-15
適應症：Epilepsy in Children、Epilepsy
Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis（NCT07697456）
贊助者：AbbVie｜階段：PHASE2｜狀態：RECRUITING｜更新日：2026-10-15
適應症：Crohn's Disease、Ulcerative Colitis
Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)（NCT07711002）
贊助者：AstraZeneca｜階段：PHASE3｜狀態：RECRUITING｜更新日：2026-10-15
適應症：Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
A Real World Evidence Retrospective Data Collection Study of Edoxaban and Rivaroxaban（NCT07874555）
贊助者：Daiichi Sankyo｜階段：未列階段｜狀態：COMPLETED｜更新日：2026-10-15
適應症：Atrial Fibrillation、Renal Dysfunction
Integrated Near-Infrared Spectroscopy and Hemodynamic Monitoring for Cerebral Autoregulation in Post-Cardiac Arrest Care Neuroprognostication（NCT07875348）
贊助者：National Taiwan University Hospital｜階段：未列階段｜狀態：NOT_YET_RECRUITING｜更新日：2026-10-15
適應症：Cardiac Arrest (CA)
Comparison of the Therapeutic Effects of Lyophilized Platelet-rich Plasma Lysate and Dextrose Prolotherapy in Knee Osteoarthritis（NCT07875543）
贊助者：Taichung Veterans General Hospital｜階段：PHASE2｜狀態：COMPLETED｜更新日：2026-10-15
適應症：Knee Osteoarthritis、Platelet-rich Plasma (PRP)
Fabry Disease Registry & Pregnancy Sub-registry（NCT00196742）
贊助者：Genzyme, a Sanofi Company｜階段：未列階段｜狀態：RECRUITING｜更新日：2026-10-14
適應症：Fabry Disease
A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer（NCT02107703）
贊助者：Eli Lilly and Company｜階段：PHASE3｜狀態：ACTIVE_NOT_RECRUITING｜更新日：2026-10-14
適應症：Breast Neoplasms
To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.（NCT03330847）
贊助者：AstraZeneca｜階段：PHASE2｜狀態：ACTIVE_NOT_RECRUITING｜更新日：2026-10-14
適應症：Metastatic Triple Negative Breast Cancer
A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer（NCT03456076）
贊助者：Hoffmann-La Roche｜階段：PHASE3｜狀態：ACTIVE_NOT_RECRUITING｜更新日：2026-10-14
適應症：Carcinoma, Non-Small-Cell Lung
A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy（NCT03762850）
贊助者：Travere Therapeutics, Inc.｜階段：PHASE3｜狀態：COMPLETED｜更新日：2026-10-14
適應症：Immunoglobulin A Nephropathy
A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor（NCT04008797）
贊助者：Eisai Inc.｜階段：PHASE1 / PHASE2｜狀態：ACTIVE_NOT_RECRUITING｜更新日：2026-10-14
適應症：Endometrial Neoplasms、Neoplasms、Carcinoma, Hepatocellular、Liver Neoplasms、Colorectal Neoplasms
A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1（NCT04534205）
贊助者：BioNTech SE｜階段：PHASE2 / PHASE3｜狀態：ACTIVE_NOT_RECRUITING｜更新日：2026-10-14
適應症：Unresectable Head and Neck Squamous Cell Carcinoma、Metastatic Head and Neck Cancer、Recurrent Head and Neck Cancer
ONO-4538 Phase II Rollover Study (ONO-4538-98)（NCT04566380）
贊助者：Ono Pharmaceutical Co., Ltd.｜階段：PHASE2｜狀態：RECRUITING｜更新日：2026-10-14
適應症：Pan-tumor
Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder（NCT05512377）
贊助者：Boehringer Ingelheim｜階段：PHASE2｜狀態：COMPLETED｜更新日：2026-10-14
適應症：Pancreatic Neoplasms、Solid Tumors、Biliary Tract Cancer、Lung Neoplasms、Bladder Cancer
A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B（NCT05611801）
贊助者：Pfizer｜階段：PHASE3｜狀態：RECRUITING｜更新日：2026-10-14
適應症：Hemophilia A、Hemophilia B
Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2)（NCT05624749）
贊助者：Novartis Pharmaceuticals｜階段：PHASE3｜狀態：ACTIVE_NOT_RECRUITING｜更新日：2026-10-14
適應症：Systemic Lupus Erythematosus
A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)（NCT05629585）
贊助者：AstraZeneca｜階段：PHASE3｜狀態：ACTIVE_NOT_RECRUITING｜更新日：2026-10-14
適應症：Breast Cancer
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer（NCT05827081）
贊助者：Novartis Pharmaceuticals｜階段：PHASE3｜狀態：RECRUITING｜更新日：2026-10-14
適應症：Early Breast Cancer
Phase 3b Study to Assess the Efficacy, Safety, and Tolerability of Remibrutinib in Comparison to Placebo, With Omalizumab as Active Control, in Adult CSU Patients, Followed by an Open-label 52-week Optional Extension.（NCT06042478）
贊助者：Novartis Pharmaceuticals｜階段：PHASE3｜狀態：ACTIVE_NOT_RECRUITING｜更新日：2026-10-14
適應症：Chronic Spontaneous Urticaria
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400（NCT06084481）
贊助者：AbbVie｜階段：PHASE1｜狀態：RECRUITING｜更新日：2026-10-14
適應症：Hepatocellular Carcinoma、Pancreatic Ductal Adenocarcinoma、Biliary Tract Cancers、Esophageal Squamous Cell Carcinoma、Triple Negative Breast Cancer、Hormone Receptor+/Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer、Head and Neck Squamous-Cell Carcinoma、Platinum Resistant High Grade Epithelial Ovarian Cancer
A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast（NCT06238622）
贊助者：Boehringer Ingelheim｜階段：PHASE3｜狀態：ACTIVE_NOT_RECRUITING｜更新日：2026-10-14
適應症：Idiopathic Pulmonary Fibrosis、Progressive Pulmonary Fibrosis
EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)（NCT06531824）
贊助者：Boehringer Ingelheim｜階段：PHASE3｜狀態：ACTIVE_NOT_RECRUITING｜更新日：2026-10-14
適應症：Kidney Disease, Chronic
A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.（NCT06629779）
贊助者：Pfizer｜階段：PHASE3｜狀態：RECRUITING｜更新日：2026-10-14
適應症：Metastatic Castration-Resistant Prostate Cancer
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis（NCT06632444）
贊助者：Boehringer Ingelheim｜階段：PHASE3｜狀態：RECRUITING｜更新日：2026-10-14
適應症：Metabolic Dysfunction Associated Steatohepatitis (MASH)、Liver Fibrosis
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis（NCT06632457）
贊助者：Boehringer Ingelheim｜階段：PHASE3｜狀態：RECRUITING｜更新日：2026-10-14
適應症：Metabolic Dysfunction Associated Steatohepatitis
Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD（NCT06813911）
贊助者：Novartis Pharmaceuticals｜階段：PHASE3｜狀態：ACTIVE_NOT_RECRUITING｜更新日：2026-10-14
適應症：Atherosclerotic Cardiovascular Disease (ASCVD)
The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis（NCT06872892）
贊助者：Boehringer Ingelheim｜階段：PHASE3｜狀態：RECRUITING｜更新日：2026-10-14
適應症：Bronchiectasis
Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations（NCT06915753）
贊助者：Tyra Biosciences, Inc｜階段：PHASE1｜狀態：RECRUITING｜更新日：2026-10-14
適應症：Metastatic Hepatocellular Carcinoma、Solid Tumors、Solid Tumor, Adult、FGFR Gene Amplification、FGFR Gene Alterations、Advanced Solid Tumors、FGFR4 Gene Mutation、FGFR4 Gene Fusions、FGF19 Gene Amplification、FGF19 Gene Overexpression、Locally Advanced Unresectable Hepatocellular Carcinoma
A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)（NCT06935357）
贊助者：Biogen｜階段：PHASE3｜狀態：RECRUITING｜更新日：2026-10-14
適應症：Immunoglobulin A Nephropathy (IgAN)
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart（NCT06935370）
贊助者：Boehringer Ingelheim｜階段：PHASE3｜狀態：RECRUITING｜更新日：2026-10-14
適應症：Heart Failure
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue（NCT06989437）
贊助者：Pfizer｜階段：PHASE2 / PHASE3｜狀態：RECRUITING｜更新日：2026-10-14
適應症：Cachexia、Metastatic Pancreatic Ductal Adenocarcinoma
An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)（NCT06991556）
贊助者：Novartis Pharmaceuticals｜階段：PHASE2｜狀態：ACTIVE_NOT_RECRUITING｜更新日：2026-10-14
適應症：Metastatic Hormone-sensitive Prostate Cancer
A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised（NCT07013474）
贊助者：Pfizer｜階段：PHASE3｜狀態：RECRUITING｜更新日：2026-10-14
適應症：COVID-19 Infection
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.（NCT07028853）
贊助者：Pfizer｜階段：PHASE3｜狀態：RECRUITING｜更新日：2026-10-14
適應症：Metastatic Castration Sensitive Prostate Cancer (mCSPC)、Hormone Sensitive Prostate Cancer、Prostate Cancer、Cancer of the Prostate
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease（NCT07064473）
贊助者：Boehringer Ingelheim｜階段：PHASE3｜狀態：RECRUITING｜更新日：2026-10-14
適應症：Diabetes Mellitus, Type 2、Hypertension、Cardiovascular Diseases
A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma（NCT07123454）
贊助者：AstraZeneca｜階段：PHASE1 / PHASE2｜狀態：RECRUITING｜更新日：2026-10-14
適應症：B-cell Non-Hodgkin Lymphoma
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations（NCT07185997）
贊助者：ArriVent BioPharma, Inc.｜階段：PHASE3｜狀態：RECRUITING｜更新日：2026-10-14
適應症：Non-Small-Cell Lung Cancer、Metastatic Non-Small-Cell Lung Cancer、Advanced Non-Small-Cell Lung Cancer、EGFR P-Loop and Alpha C-Helix Compressing、EGFR PACC、EGFR Uncommon Mutations
Immediate Effects of Manual and Verbal Cueing During Movement Control Training in Chronic Non-Specific Low Back Pain（NCT07324538）
贊助者：National Yang Ming Chiao Tung University｜階段：NA｜狀態：RECRUITING｜更新日：2026-10-14
適應症：Chronic Low Back Pain (Non-specific, Uncomplicated)
A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)（NCT07409181）
贊助者：Boehringer Ingelheim｜階段：PHASE2｜狀態：RECRUITING｜更新日：2026-10-14
適應症：Systemic Lupus Erythematosus
A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis（NCT07497087）
贊助者：Boehringer Ingelheim｜階段：PHASE3｜狀態：RECRUITING｜更新日：2026-10-14
適應症：Systemic Sclerosis
An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)（NCT07517263）
贊助者：Novartis Pharmaceuticals｜階段：PHASE3｜狀態：ACTIVE_NOT_RECRUITING｜更新日：2026-10-14
適應症：Cardiovascular Disease and Lipoprotein(a)
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease（NCT07577843）
贊助者：Janssen Research & Development, LLC｜階段：PHASE3｜狀態：RECRUITING｜更新日：2026-10-14
適應症：Crohn Disease
A Study to Understand How Nerandomilast Works in People With Active Idiopathic Inflammatory Myopathies（NCT07789015）
贊助者：Boehringer Ingelheim｜階段：PHASE3｜狀態：NOT_YET_RECRUITING｜更新日：2026-10-14
適應症：Idiopathic Inflammatory Myopathies
Effects of Resistance Training on Recovery During Hematopoietic Stem Cell Transplantation（NCT07872813）
贊助者：Taipei Veterans General Hospital, Taiwan｜階段：NA｜狀態：NOT_YET_RECRUITING｜更新日：2026-10-14
適應症：Hematologic Malignancies、Hematopoietic Stem Cell Transplantation、Resistance Training、Neutropenia、Acute Graft-versus-Host Disease、Cancer-related Fatigue、Muscle Strength
Co-contraction and Corticoreticular Excitability in Spinal Cord Injury（NCT07872839）
贊助者：Taipei Veterans General Hospital, Taiwan｜階段：NA｜狀態：ENROLLING_BY_INVITATION｜更新日：2026-10-14
適應症：Spinal Cord Injury、Spasticity
資料來源：ClinicalTrials.gov 公開登錄資料，每日台北時間07點與19點擷取。登錄狀態不代表試驗結果。